Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW501516 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| GW501516 oral tablets | DRUG | - |
Inclusion criteria: * Have a fasting plasma HDLc concentration \<=45mg/dL (\<=1.16mmol/L), plasma LDLc levels that do not require treatment according to the National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATPÂ III) guidelines. * Have a fasting plasma TG concentration =500mg/d...
GW501516 is an investigational small molecule being studied for the treatment of dyslipidaemias, conditions involving abnormal levels of lipids in the blood. It was evaluated in a Phase 2 clinical trial in subjects who had low levels of high-density lipoprotein cholesterol. The drug is not approved and remains in clinical development.
GW501516 is being developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker GSK. The company sponsored a Phase 2 clinical trial of the drug in patients with dyslipidaemia.
GW501516 is in Phase 2 clinical development. It has completed one Phase 2 trial, which enrolled 424 participants. The drug is investigational and has not been approved for any use.
GW501516 has been studied in one completed Phase 2 clinical trial, identified as NCT00158899. The trial was titled 'GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol' and enrolled 424 participants with dyslipidaemia across multiple European countries.
The Phase 2 clinical trial of GW501516 was randomized and double-blind, meaning neither the participants nor the investigators knew which treatment was being administered. The trial did not use a control group and was not biomarker-selected.
GW501516 is also known by its chemical name and is sometimes referred to as a PPAR delta agonist. However, no alternative brand names have been established for this investigational compound.